Former President Jimmy Carter has melanoma and will begin undergoing radiation treatment today for four melanoma tumors in his brain, he told reporters at the Carter Center in Atlanta.
Skin cancer is the most common form of cancer in the United States, with more than one million new cases each year. Skin cancer is often divided into two broad categories: melanoma and non-melanoma. Non-melanoma skin cancer refers to several different types of skin cancer, but the most common types are basal cell carcinoma and squamous cell carcinoma.
Melanoma is less common than non-melanoma skin cancer, but tends to be much more aggressive. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each year in the United States. What makes melanoma so dangerous is that it is more likely than other types of skin cancer to spread (metastasize) to other parts of the body. Melanoma can occur anywhere on the body. The first signs of melanoma may be a mole that changes in appearance, bleeds, or has more than one color or an irregular shape.
After years with progress, several exciting developments in melanoma therapy have recently occurred. Doctors specializing in the treatment of melanoma have reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy drugs have become available for the management of patients with advanced disease.
Here is a recent summary of major advances in the management of melanoma:
FDA News in Melanoma:
- FDA Approves Nivolumab for Advanced Melanoma
- Pembrolizumab Gets FDA Approval in Advanced Melanoma
- FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma
- Yervoy® Improves Treatment of Stage III Melanoma
- Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma
- Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma
- Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma
- Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity
- Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma
- Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results
- Nivolumab Produces Durable Responses in Advanced Melanoma
- Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients
- Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures
- T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma
Understanding DNA Damage Response or DDR and Cancer Treatment
What is DNA Damage Response or DDR?
BRAF/MEK Inhibitor News
- COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma
- BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials
- Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover
Ocular Melanoma News:
Intralesional Therapy for Melanoma:
LEARN MORE ABOUT MELANOMA
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?
- Sign up for monthly newsletters on melanoma here.
- Get the facts about melanoma here.
- Join ongoing discussions with other individuals affected by melanoma in the CancerConnect private online support group here.
- Follow CancerConnect on Facebook and Twitter.
Copyright © 2018 CancerConnect. All Rights Reserved.